ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.32M | 30K -97.73% | 20.055M 66,750.00% | 122.06M 508.63% | 223.02M 82.71% | 314.55M 41.04% | 492.02M 56.42% | 629.47M 27.94% | 779.73M 23.87% | 942.44M 20.87% | 740.18M -21.46% | ||
| EBITDA YoY % growth | -88.8M -175.09% | -35.2M 60.36% | -67.447M -91.61% | -26.306M 61.00% | -49.558M -88.39% | 109.7M 321.36% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -89.58M -172.11% | -35.52M 60.35% | -67.52M -90.09% | -68.691M -1.73% | -47.62M 30.68% | 2.7M 105.67% | 50.031M 1,753.00% | 168.76M 237.31% | 286.34M 69.67% | 407.29M 42.24% | 521.72M 28.10% | 411.43M -21.14% | |
| Operating Margin | N/A | -2,690.91% | -225,066.67% | -342.51% | -39.01% | 1.21% | 15.91% | 34.30% | 45.49% | 52.23% | 55.36% | 55.59% | |
| EPS YoY % growth | -2.56 -10.08% | -0.98 61.72% | -0.57 41.84% | -0.59 -4.24% | -0.37 37.34% | 0.07 119.86% | 0.47 541.38% | 1.17 147.31% | 2.06 75.65% | 3.15 52.97% | 4.25 34.95% | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 1.64% | -0.24 -119.46% | -0.21 -59.54% | -0.22 -10.50% | -0.13 -82.71% | -0.06 74.65% | 0.21 203.28% | 0.50 326.15% | 0.30 335.14% |
| Revenue Q2Q % growth | 25.987M | 10.586M | 18.209M 3,541.80% | 28.457M 1,276.06% | 31.544M 21.38% | 42.738M 303.72% | 75.541M 314.86% | 114.33M 301.76% | 86.996M 175.79% |
| EBITDA Q2Q % growth | 24.929M 345.53% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.827M 13.68% | -26.323M -99.54% | -25.515M -66.33% | -32.522M -49.54% | -24.767M -180.58% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.20 -25.00% | -0.15 | -0.05 | -32.93% |
| Q2 2024 Q2Q % growth | -0.13 27.78% | -0.12 | -0.01 | -9.24% |
| Q1 2024 Q2Q % growth | -0.11 31.25% | -0.11 | 0.00 | 1.96% |
| Q4 2023 Q2Q % growth | -0.07 -109.09% | -0.14 | 0.07 | 50.98% |
| Q3 2023 Q2Q % growth | -0.16 68.00% | -0.19 | 0.03 | 14.13% |
| Q2 2023 Q2Q % growth | -0.18 67.27% | -0.18 | 0.00 | -1.61% |
| Q1 2023 Q2Q % growth | -0.16 77.14% | -0.17 | 0.01 | 6.45% |
| Q4 2022 Q2Q % growth | 0.77 214.93% | -0.13 | 0.90 | 680.69% |
| Q3 2022 Q2Q % growth | -0.50 23.08% | -0.36 | -0.14 | -38.08% |
| Q2 2022 Q2Q % growth | -0.55 21.43% | -0.49 | -0.06 | -11.56% |
| Q1 2022 Q2Q % growth | -0.70 -29.63% | -0.55 | -0.15 | -28.04% |
| Q4 2021 Q2Q % growth | -0.67 51.09% | -0.72 | 0.05 | 6.43% |
| Q3 2021 Q2Q % growth | -0.65 | -0.69 | 0.04 | 5.45% |
| Q2 2021 Q2Q % growth | -0.70 | -0.54 | -0.16 | -28.68% |
| Q1 2021 Q2Q % growth | -0.54 | -0.36 | -0.18 | -49.13% |
| Q4 2020 Q2Q % growth | -1.37 | -0.50 | -0.87 | -174.11% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.068M | 586.5K | 1.482M | 252.60% |
| Q2 2024 Q2Q % growth | 500K 4,900.00% | 1.02M | -520K | -50.98% |
| Q1 2024 Q2Q % growth | -100.00% | % | ||
| Q4 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | 1.32M | 96.39K | 1.224M | 1,269.44% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 70.65% | -18.27% | 12.08% |
| Revenue | 0% | 487.01% | -30.09% | 367.27% |